Neuphoria Therapeutics Inc. (NEUP) NASDAQ
4.51
-0.1(-2.17%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.51
-0.1(-2.17%)
Currency In USD
| Previous Close | 4.61 |
| Open | 4.52 |
| Day High | 4.61 |
| Day Low | 4.47 |
| 52-Week High | 21.4 |
| 52-Week Low | 3.65 |
| Volume | 68,257 |
| Average Volume | 48,777 |
| Market Cap | 8.48M |
| PE | -6.54 |
| EPS | -0.69 |
| Moving Average 50 Days | 4.25 |
| Moving Average 200 Days | 7 |
| Change | -0.1 |
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology c
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
GlobeNewswire Inc.
Dec 04, 2025 1:00 PM GMT
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE N
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals a